Drug Giant Lilly to Cut 14% of Staff, $1B in Costs
September 15, 2009
The Indianapolis company said it will reduce its work force by nearly 14 percent, to 35,000 from the current 40,500, by the end of 2011. The new total excludes hirings in high-growth emerging markets and Japan.
September 15, 2009
The Indianapolis company said it will reduce its work force by nearly 14 percent, to 35,000 from the current 40,500, by the end of 2011. The new total excludes hirings in high-growth emerging markets and Japan.
In Crisis or Calm
April 1, 2009 by Mike Egan
In order to effectively react to a crisis, boards and management need to be able to respond quickly to changing circumstances, while avoiding hasty (and perhaps ill-advised) decision-making.
April 1, 2009 by Mike Egan
In order to effectively react to a crisis, boards and management need to be able to respond quickly to changing circumstances, while avoiding hasty (and perhaps ill-advised) decision-making.
Doubts Cloud Lilly-ImClone Deal
October 10, 2008 by Joseph McCafferty
After Eli Lilly agreed to buy ImClone Systems for $6.5 billion, a growing number of analysts questioned whether Lilly had overpaid. Whether or not Lilly will be able to raise the money is under scrutiny.
October 10, 2008 by Joseph McCafferty
After Eli Lilly agreed to buy ImClone Systems for $6.5 billion, a growing number of analysts questioned whether Lilly had overpaid. Whether or not Lilly will be able to raise the money is under scrutiny.
Lilly to Buy ImClone for $6.5 Billion
October 6, 2008 by Joseph McCafferty
Eli Lilly said it agreed to acquire ImClone Systems in an all-cash deal the companies valued at $6.5 billion. The $70-per-share bid beat out Bristol-Meyers Squibb’s $62-per-share offer.
October 6, 2008 by Joseph McCafferty
Eli Lilly said it agreed to acquire ImClone Systems in an all-cash deal the companies valued at $6.5 billion. The $70-per-share bid beat out Bristol-Meyers Squibb’s $62-per-share offer.
Eli Lilly in Talks to Buy ImClone
October 2, 2008 by Joseph McCafferty
Eli Lilly is the unnamed "large pharma company" that activist investor and ImClone chairman, Carl Icahn, said is prepared to acquire the company for about $70-per-share.
October 2, 2008 by Joseph McCafferty
Eli Lilly is the unnamed "large pharma company" that activist investor and ImClone chairman, Carl Icahn, said is prepared to acquire the company for about $70-per-share.
ImClone’s Sale Talks Continue
September 29, 2008 by Joseph McCafferty
ImClone Systems is expected to announce later today that it is continuing talks to sell itself to a major pharmaceutical concern for a price in the range of $6.1 billion. Activist investor Carl Icahn has been searching for a higher bid.
September 29, 2008 by Joseph McCafferty
ImClone Systems is expected to announce later today that it is continuing talks to sell itself to a major pharmaceutical concern for a price in the range of $6.1 billion. Activist investor Carl Icahn has been searching for a higher bid.
The 2008 List of Influentials on the Directorship 100
September 1, 2008 by Directorship Editors
The Most Influential Players in Corporate Governance (listed in alphabetical order)
September 1, 2008 by Directorship Editors
The Most Influential Players in Corporate Governance (listed in alphabetical order)
CalPERS Won’t Support Lily CEO
March 28, 2008 by Joseph McCafferty
The California Public Employees' Retirement System (CalPERS) said yesterday that it plans to withhold re-election votes for three directors of Eli Lilly and Co.
March 28, 2008 by Joseph McCafferty
The California Public Employees' Retirement System (CalPERS) said yesterday that it plans to withhold re-election votes for three directors of Eli Lilly and Co.